Surgery Partners, Inc. (SGRY)
NASDAQ: SGRY · Real-Time Price · USD
17.19
-0.19 (-1.09%)
At close: Dec 5, 2025, 4:00 PM EST
17.35
+0.16 (0.93%)
After-hours: Dec 5, 2025, 7:52 PM EST
Surgery Partners Stock Forecast
Stock Price Forecast
The 9 analysts that cover Surgery Partners stock have a consensus rating of "Buy" and an average price target of $27.44, which forecasts a 59.63% increase in the stock price over the next year. The lowest target is $18 and the highest is $36.
Price Target: $27.44 (+59.63%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Surgery Partners stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 2 | 2 | 2 |
| Buy | 3 | 3 | 3 | 3 | 3 | 4 |
| Hold | 3 | 3 | 3 | 4 | 4 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Hold Maintains $27 → $20 | Hold | Maintains | $27 → $20 | +16.35% | Nov 24, 2025 |
| Barclays | Barclays | Hold Maintains $24 → $18 | Hold | Maintains | $24 → $18 | +4.71% | Nov 21, 2025 |
| Mizuho | Mizuho | Buy Maintains $28 → $22 | Buy | Maintains | $28 → $22 | +27.98% | Nov 17, 2025 |
| UBS | UBS | Strong Buy Maintains $34 → $29 | Strong Buy | Maintains | $34 → $29 | +68.70% | Nov 13, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $35 → $31 | Buy | Maintains | $35 → $31 | +80.34% | Nov 11, 2025 |
Financial Forecast
Revenue This Year
3.36B
from 3.11B
Increased by 7.76%
Revenue Next Year
3.63B
from 3.36B
Increased by 8.16%
EPS This Year
0.66
from -1.33
EPS Next Year
0.75
from 0.66
Increased by 13.81%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.5B | 3.9B | |||
| Avg | 3.4B | 3.6B | |||
| Low | 3.2B | 3.4B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 11.7% | 14.9% | |||
| Avg | 7.8% | 8.2% | |||
| Low | 3.1% | -0.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.91 | 0.97 | |||
| Avg | 0.66 | 0.75 | |||
| Low | 0.52 | 0.28 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 46.6% | |||
| Avg | - | 13.8% | |||
| Low | - | -56.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.